^
    Back
    Association details:
    Biomarker:RET rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

    Excerpt:
    ...- Phase 2 Cohort C (thyroid cancer): Subjects must have a histologically or cytologically confirmed diagnosis of metastatic thyroid cancer (Stage IV) that carries either a RET rearrangement or activating RET mutation, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDT....
    Trial ID:
    NCT03131206
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

    Excerpt:
    This study was a single-arm, open-label, multi-institutional P1/2 trial. Previously treated patients with RET-rearranged NSCLC...In P1, alectinib (600 or 450 mg BID) was administered...In 25 RET inhibitor-naïve patients, one achieved an objective response (4%) and 13 achieved disease control at 8 weeks (52%).
    DOI:
    10.21037/tlcr-20-549
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Thorac Oncol
    Title:

    Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer

    Excerpt:
    Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors.
    DOI:
    10.1016/j.jtho.2016.08.126